Dalpiciclib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Dalpiciclib
- Molecular weight
- 446.56
- Structure (SMILES)
- CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
- adebrelimab and dalpiciclib
- cdk4 6 inhibitor shr6390
- CDK4/6 INHIBITOR SHR6390
- dalpiciclib
- Dalpiciclib
- dalpiciclib [INN]
- Dalpiciclib [WHO-DD]
- Dalpiciclib 100mg
- Dalpiciclib 125mg
- Dalpiciclib 150mg
- dalpiciclib inn
- dalpiciclib who dd
- pyrido 2 3 d pyrimidin 7 8h one 6 acetyl 8 cyclopentyl 5 methyl 2 5 4 piperidinyl 2 pyridinyl amino
- PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(4-PIPERIDINYL)-2-PYRIDINYL)AMINO)-
- shr 6390
- Shr-6390
- SHR-6390
- CAS registry numbers
- 1637781-04-4
- ChEMBL ID
- CHEMBL4802161
- InChIKey
- SGJLSPUSUBJWHO-UHFFFAOYSA-N
- PubChem compound IDs
- 86279927
- FDA ingredient codes (UNII)
- 5ZHA5P4PFX
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- dalpiciclib
- Type
- Synthetic organic
- Drug name stem
- -ciclib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 4
- Gene symbol
- CDK4
- Protein identifier
- P11802
- Median affinity
- 7.96
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 6
- Gene symbol
- CDK6
- Protein identifier
- Q00534
- Median affinity
- 8.22
- Affinity units
- pIC50
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001075
- Subject identifier
- D010051
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Nasopharyngeal Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0015459
- Subject identifier
- D000077274
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001075
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004950
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004990
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005494
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 2
And 2 more, listed on the interactive page.
- NCT02671513
- NCT02684266
- NCT05512780
- NCT03480256
- NCT03481998
- NCT03772353
- NCT03927456
- NCT04095390
- NCT04236310
- NCT04293276
- NCT04355858
- NCT04733417
- NCT04842617
- NCT04997798
- NCT05176080
- NCT05431504
- NCT05463601
- NCT05469750
- NCT05512416
- NCT05515289
- NCT05574881
- NCT05577923
- NCT05586841
- NCT05638594
- NCT05759546
And 19 more, listed on the interactive page.
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 101.8
- Calculated partition coefficient (ALogP)
- 4.02
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 33
- Molecular formula
- C25H30N6O2
- Monoisotopic mass
- 446.24302422
- Natural product
- No
- Recorded assays
- 5
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (69)
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
- A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
- Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
- Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC
- An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- An Exploratory Clinical Study of Dalpiciclib an'd Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
- An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
- Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
- Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
- CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
- Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
- Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
- Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
- Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
- Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
In development for (12)
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Esophageal squamous cell carcinoma Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Gastric cancer Phase 1
- Head and neck squamous cell carcinoma Phase 2
- Liver disorder Phase 1
- Melanoma Phase 1
- Nasopharyngeal carcinoma Phase 2
- Neoplasm Phase 2
- Ovarian carcinoma Phase 2
- Sarcoma Phase 2